Merck (MRK) is down -10.1%, or -$10.10 to $89.69. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended ...
Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates. “This sales ...
Merck shares tumbled after the drugmaker said ... In results published on Tuesday, the pharmaceutical group forecast full-year sales of between $64.1bn and $65.6bn in 2025, broadly flat compared ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.
Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.
Merck achieved revenue growth in Q4, but stocks tumbled Tuesday amid news that the company is pausing Gardasil shipments to China. © 2024 Fortune Media IP Limited ...
Merck swung to a quarterly profit as sales grew to beat Wall Street’s estimates, though the drug company’s outlook for 2025 and a slide in sales of its HPV vaccine, Gardasil, hit shares. The ...
The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant prostate cancer ...
Stocks saw a massive turnaround during Monday’s volatile trading session on news of the pausing of U.S. tariffs against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback